Executive Summary
The 16 filings reveal a surge in SPAC activity with 10 new or progressing blank check companies (IPOs, unit separations, extensions, and de-SPAC advancements), signaling robust M&A appetite amid a tight deadline environment, while 5 major acquisitions completed on May 14, 2026, across pharma (Apellis/Biogen), telecom (CSG/NEC), marine (Off The Hook/Apex), and homebuilding (Tri Pointe/Sumitomo). Period-over-period trends show SPACs like Boost Run (Willow Lane) posting net income growth to $3.4M in 2025 from $0.1M in 2024 driven by trust interest, but cash declines and widening deficits highlight liquidity strains common to 4/16 filings. Completed deals emphasize accretive synergies (Biogen EPS boost 2027, Off The Hook millions in savings), with forward-looking catalysts like CVRs up to $4/share and Phase 3 data H1 2027. Portfolio-level patterns indicate SPAC extensions averting liquidation (e.g., GP-Act III to Nov 2026), but going concern doubts in 3 SPACs and proxy risks in Mountain Lake underscore execution risks. Market implications include heightened M&A momentum in US equities, favoring acquirers like Biogen and Sumitomo for growth, while SPACs offer de-SPAC alpha if targets materialize.
Tracking the trend? Catch up on the prior US Merger & Acquisition SEC Filings digest from May 06, 2026.
Investment Signals (12)
- Apellis Pharmaceuticals (Biogen Acquisition) (BULLISH)▲
Completed tender with 82.4% shares (105.7M) tendered at $41/share + $4 CVR; Apellis 2025 revenue $689M adds to Biogen pipeline, accretive to Non-GAAP EPS 2027
- Biogen Inc. ↓ (BULLISH)▲
Acquired Apellis for EPS CAGR boost through decade, felzartamab Phase 3 H1 2027; updated guidance Q2 earnings July 2026 outperforms sector M&A
- CSG Systems (NEC/Netcracker Acquisition) (BULLISH)▲
Deal completion enhances AI/cloud capabilities for telecom; no service disruptions, leadership continuity with Feinberg as CEO
- Off The Hook YS Inc. ↓ (BULLISH)▲
Acquired Apex adding 150MT haul-out capacity, vessels to 130ft; millions in annual savings from integration in $57B marine industry
- Tri Pointe Homes (Sumitomo Acquisition) (BULLISH)▲
$47/share deal positions combined entity as #5 US homebuilder with 15K units/year across 18 states, targeting 23K by 2030
- Shreya Acquisition Group ↓ (BULLISH)▲
IPO raised $110M (11M units) + $1.9M private; no over-allotment costs, NYSE listing supports rapid de-SPAC
- Vernal Capital Acquisition Corp. ↓ (BULLISH)▲
IPO $100M public + $2.5M private into trust; unit separation May 19 enables liquidity, founder shares restated
- GP-Act III Acquisition Corp. ↓ (BULLISH)▲
Extended business combination deadline to Nov 13, 2026 via shareholder vote, averting liquidation
- Boost Run Inc. (Willow Lane SPAC) ↓ (BULLISH)▲
Net income $3.4M 2025 (vs $0.1M 2024) from $5.4M trust interest; merger financials filed, redemption value up to $10.48
- Real Asset Acquisition Corp. ↓ (BULLISH)▲
IQM F-4 filed advancing Feb 2026 merger to public; preliminary proxy for EGM
- Melar Acquisition Corp. I ↓ (BULLISH)▲
Entered material merger agreement, financial exhibits filed; high materiality despite details pending
- CSG Systems ↓ (BULLISH)▲
Post-acquisition focus on customer engagement/monetization strengthens vs pre-deal standalone
Risk Flags (10)
- ▼
Auditor doubt if no business combination in 15-21 months; equity $0.8M vs $101M assets, cash outside trust $0.9M
- Boost Run Inc. (Willow Lane, Liquidity)↓ [HIGH RISK]▼
Cash down to $323K from $1.4M YoY, shareholders' deficit $(4.9M) vs $(2.9M); going concern if no deal by Nov 12, 2026
- Mountain Lake Acquisition Corp. (Proxy Risks)↓ [HIGH RISK]▼
DEFM14A flags internal controls, litigation, stock volatility, MAE clauses, Nasdaq conditions; emerging growth exemptions
- Fifth Era Acquisition Corp I (Leadership)↓ [MEDIUM RISK]▼
CFO Christopher Linn resigned immediately; new CFO Nelson (age 29) unproven at scale despite prior SPAC support
- Blue Water Acquisition Corp. IV (Board)↓ [MEDIUM RISK]▼
Director Laurent Hermouet resigned immediately, no replacement yet; searching actively
- Apellis Pharmaceuticals (Notes Repurchase) [MEDIUM RISK]▼
$94M 3.5% notes convertible til June 29 or repurchase June 30 at 100% + interest; make-whole premium adds CVRs
- Vernal Capital Acquisition Corp. (Over-allotment)↓ [MEDIUM RISK]▼
$135K liability, $75K trust for over-allotment; founder shares forfeiture risk up to 375K
- Mountain Lake (Conflicts) [MEDIUM RISK]▼
Advisory board affiliations risk resource diversion; post-merger volatility unrelated to performance
- GP-Act III (No Financials)↓ [LOW-MEDIUM RISK]▼
Extension filed but no metrics disclosed, relies on prior IPO timeline
- RRE Ventures Acquisition Corp.↓ [LOW RISK]▼
Underwriters forfeited over-allotment May 14, potential sizing signal
Opportunities (10)
- Biogen Inc. (Apellis Integration)↓ (OPPORTUNITY)◆
$689M 2025 revenue addition, EPS accretive 2027, felzartamab H1 2027 data; trading halt creates post-deal rerating
- Off The Hook YS (Apex Synergies) (OPPORTUNITY)◆
Millions in savings, centralized $10sM inventory hub in $57B industry; South FL capacity expansion
- Tri Pointe Homes (Sumitomo Scale) (OPPORTUNITY)◆
#5 homebuilder 15K units to 23K by 2030; premium brand across 18 states
- Real Asset Acquisition Corp. (IQM De-SPAC)↓ (OPPORTUNITY)◆
F-4/proxy filed post-Feb 2026 agreement; EGM upcoming for quantum tech public listing
- Melar Acquisition Corp. I (New Merger) (OPPORTUNITY)◆
Material agreement entered May 14; exhibits provide early diligence edge
- Shreya Acquisition Group (Fresh IPO)↓ (OPPORTUNITY)◆
$112M total proceeds, emerging growth status; target hunt in early phase
- GP-Act III (Extended Runway)↓ (OPPORTUNITY)◆
Deadline to Nov 2026; shareholder-approved avoids liquidation
- Vernal Capital (Unit Separation) (OPPORTUNITY)◆
Trading starts May 19 (VECA/VECAR); post-IPO liquidity unlocks trading
- Boost Run (Merger Financials) (OPPORTUNITY)◆
Audited statements filed; trust yield supports $10.48 redemption vs cash strain
- CSG Systems/Netcracker (Telecom AI)↓ (OPPORTUNITY)◆
Combined platforms for monetization/automation; 30+ years Netcracker experience
Sector Themes (6)
- SPAC Resurgence & Extensions◆
10/16 filings SPAC-related; 3 IPOs raised $320M+ total (Vernal $103M, Shreya $112M), 1 extension to Nov 2026, 3 unit separations May 19-20; implies M&A pipeline strength but liquidity risks in 3 [Bullish for de-SPAC hunters]
- M&A Completions Cluster May 14◆
5/16 deals closed same day (Apellis/Biogen, CSG/NEC, Off The Hook/Apex, Tri Pointe/Sumitomo); $41-47/share premiums + CVRs/synergies signal peaking activity [Favors acquirers like Biogen/Sumitomo]
- Going Concern Pressures in SPACs◆
3/10 SPACs flag doubts (Vernal 15-21mo, Boost Run Nov 2026, implied GP-Act); cash declines YoY (Boost $1.4M to $0.3M), deficits widen; avg equity <1% of trusts [Heightens redemption risks]
- Leadership Transitions Neutral◆
3 resignations (Fifth Era CFO, Blue Water director, no disagreements); quick replacements/infill maintain momentum [Low sector impact]
- Forward Synergies in Completions◆
Accretion/EPS growth (Biogen 2027), savings (Off The Hook millions), scale (Tri Pointe 15K->23K units); CVRs/milestones add upside [Drives post-deal performance]
- Proxy/Registration Progress◆
3 filings advance de-SPACs (Real Asset F-4, Mountain Lake DEFM14A, Melar agreement); conditions like EGM/Nasdaq focus execution hurdles [Monitor for closings]
Watch List (8)
- Apellis Notes Holders👁
Conversion election/make-whole to June 29, 2026; repurchase June 30 at $1,008.46/$1K principal + CVRs [Liquidity event]
-
Q2 earnings July 2026 for updated guidance post-Apellis; felzartamab Phase 3 H1 2027 [EPS/catalyst update]
-
EGM for IQM merger post-F-4/proxy; 10-K filed March 2026 provides baseline [Vote/de-SPAC timeline]
-
Closing conditions (shareholder approval, Nasdaq, no MAE); Pubco emerging growth status [Proxy vote risks]
-
Business combination by Nov 12, 2026 or liquidation; monitor trust $10.48 redemption [Deadline pressure]
-
Post-extension target search to Nov 13, 2026; no financials yet [Deal announcement]
-
Unit separation trading May 19 (VECA/VECAR); over-allotment/liquidation in 15-21 months [Liquidity/IPO follow-on]
-
Merger agreement details in exhibits; target/valuation disclosure [Early diligence window]
Filing Analyses
(16)
14-05-2026
Vernal Capital Acquisition Corp., a blank check company, consummated its IPO on May 7, 2026, selling 10,000,000 public units at $10.00 each for $100,000,000 gross proceeds and 251,250 private units to sponsors for $2,512,500, depositing $100,500,000 into a trust account. The balance sheet as of May 7, 2026, shows total assets of $101,518,073, with $793,727 in shareholders' equity. However, the auditor's report raises substantial doubt about the company's ability to continue as a going concern if it fails to complete an initial business combination within 15 months (or up to 21 months if extended).
- · Cash outside trust: $943,073; cash held in trust for over-allotment: $75,000.
- · Over-allotment option liability: $135,280.
- · Founder shares retroactively restated: 2,875,000 issued to sponsors for $25,000, including up to 375,000 subject to forfeiture.
- · Business combination must have fair market value of at least 80% of trust assets (excluding deferred underwriting commissions and taxes).
- · IPO registration statement effective May 5, 2026; must complete business combination within 15 months from May 7, 2026 (or up to 21 months if extended).
14-05-2026
GP-Act III Acquisition Corp. (GPATU) passed a special shareholder resolution amending its Amended and Restated Memorandum and Articles of Association, extending the deadline to consummate a Business Combination from 24 months after IPO to November 13, 2026. This change to Articles 49.9 and 49.10 provides additional time to complete a merger and avoids immediate liquidation risk. No financial metrics or performance data were disclosed in the filing.
- · Filing items: 1.01, 5.03, 5.07, 9.01
- · Amendments specifically target Article 49.9 introduction and Article 49.10 wording
- · Effective immediately upon shareholder resolution
14-05-2026
Apellis Pharmaceuticals, Inc. completed its acquisition by Biogen Inc. via tender offer and merger effective May 14, 2026, with shareholders receiving $41.00 per share in cash plus one non-transferable CVR potentially worth up to $4.00 upon milestone achievements. The company notified Nasdaq of the merger, halted trading, and plans to delist, deregister, and terminate SEC reporting obligations. Holders of the outstanding $93,897,000 principal amount of 3.500% Convertible Senior Notes due 2026 can elect to convert with a make-whole premium (yielding $1,080.77 cash and 26.3411 CVRs per $1,000 principal) until June 29, 2026, or require repurchase at 100% principal plus accrued interest (approx. $1,008.46 per $1,000) on June 30, 2026.
- · Base Conversion Rate: 25.3405 shares of Common Stock per $1,000 principal (standard); 26.3411 with Additional Shares of 1.0006 for Make-Whole Fundamental Change.
- · Make-Whole Fundamental Change Period: May 14, 2026 to June 29, 2026.
- · Fundamental Change Repurchase Date: June 30, 2026; repurchase at 100% principal plus accrued and unpaid interest.
- · Nasdaq trading halted effective before open on May 14, 2026; Form 25 to be filed for delisting.
14-05-2026
Vernal Capital Acquisition Corp., a blank check company, announced on May 14, 2026, that holders of its units (VECAU) may elect to separately trade the included ordinary shares and rights commencing on or about May 19, 2026. Ordinary shares will trade under 'VECA' and rights under 'VECAR' on the NYSE, while unsegregated units continue trading as 'VECAU'. No financial results, acquisitions, or other material changes were reported.
- · Holders must have brokers contact Continental Stock Transfer & Trust Company to separate units.
- · Company's business address: 244 Fifth Avenue, Suite #1845, New York, NY 10001; phone: +65 9328 8727.
14-05-2026
Shreya Acquisition Group, a Cayman Islands-incorporated SPAC, consummated its IPO on May 8, 2026, selling 11,000,000 units (including 1,000,000 from partial over-allotment) at $10.00 per unit for gross proceeds of $110,000,000. Simultaneously, it closed a private placement of 191,750 units to its Sponsor at $10.00 per unit, generating $1,917,500 in proceeds. An audited balance sheet reflecting these transactions is included as Exhibit 99.1.
- · Securities registered on New York Stock Exchange
- · No additional Private Units or incremental underwriting expense from partial over-allotment
- · Emerging growth company status
- · Warrants exercisable for one Class A Ordinary Share at $11.50 (subject to adjustment)
- · Rights convert to one-fourth of one Class A Ordinary Share upon initial business combination
14-05-2026
Fifth Era Acquisition Corp I, a Cayman Islands-based SPAC, announced on May 8, 2026, the resignation of Christopher Linn as Chief Financial Officer, effective immediately, with no disagreements on operations, policies, or financial reporting. The Board simultaneously appointed Christopher Nelson, age 29, as the new CFO. Mr. Nelson has supported the company's accounting, finance, and reporting functions since its IPO and has prior experience with the management team's previous SPAC and Fifth Era Partners.
- · Mr. Nelson performed similar functions for the management team’s prior SPAC from 2021 to 2024.
- · Mr. Nelson served as Investment Associate, Head of Research, and Director of Finance at Fifth Era Partners beginning in 2021.
- · Mr. Nelson consulted on executive and board compensation at Mercer beginning in 2019.
- · Company securities: Units (FERAU), Class A ordinary shares par value $0.0001 (FERA), Rights (FERAR), all listed on Nasdaq.
14-05-2026
Real Asset Acquisition Corp. (RAAQ), a SPAC, filed an 8-K on May 14, 2026, announcing that IQM Finland Oy publicly filed a Form F-4 registration statement with the SEC in connection with their February 22, 2026 business combination agreement, advancing the merger to take IQM public. The filing includes a preliminary proxy statement/prospectus for RAAQ shareholders ahead of an Extraordinary General Meeting. A joint press release was attached as Exhibit 99.1, with standard forward-looking statements and risk disclosures.
- · Business Combination Agreement dated February 22, 2026
- · Form F-4 includes preliminary proxy statement of RAAQ and preliminary prospectus of IQM
- · RAAQ Annual Report on Form 10-K for year ended December 31, 2025 filed March 3, 2026
14-05-2026
Melar Acquisition Corp. I/Cayman filed an 8-K on 2026-05-14 under Item 1.01 announcing entry into a material definitive agreement related to a merger/acquisition event. Item 9.01 discloses financial statements and exhibits, likely including the agreement details. No quantitative metrics, parties, valuation, terms, or performance data are provided in the filing summary.
14-05-2026
RRE Ventures Acquisition Corp., a Cayman Islands-incorporated SPAC, announced on May 14, 2026, that holders of its units may elect to separately trade the Class A ordinary shares and warrants comprising the units commencing May 20, 2026, with separated shares trading under 'RREV' and warrants under 'RREVW'. The company completed its initial public offering of 25,000,000 units on May 1, 2026, and the underwriters forfeited their over-allotment option on May 14, 2026. Units not separated will continue trading under 'RREVU' on Nasdaq.
- · Underwriters forfeited their over-allotment option to purchase additional units on May 14, 2026.
- · Company address: 5355 Town Center Road, Boca Raton, Florida 33486.
- · Warrants exercisable for one Class A ordinary share at $11.50 per share.
14-05-2026
On May 9, 2026, Laurent Hermouet resigned as a member of the Board of Directors of Blue Water Acquisition Corp. IV, effective immediately, including all committee memberships, with no disagreement on any matter relating to the Company’s operations, policies, or practices. The Company is actively searching for a replacement director.
14-05-2026
Willow Lane Acquisition Corp., a blank check company (SPAC), reported net income of $3,438,450 for the year ended December 31, 2025, primarily from $5,420,400 in trust interest income offsetting $2,017,653 in general and administrative costs, compared to net income of $116,890 in the 2024 inception period. However, cash balances declined to $322,830 from $1,368,608, shareholders' deficit widened to $(4,895,873) from $(2,913,923), and a going concern uncertainty exists if no business combination is completed by November 12, 2026. The filing includes audited financial statements for Willow Lane, Boost Run Holdings, LLC, and Boost Run Inc. in connection with a material merger/acquisition agreement.
- · Going concern doubt due to liquidity needs and mandatory liquidation by November 12, 2026 if no business combination.
- · Audited by WithumSmith+Brown, PC (PCAOB ID 100) for Willow Lane.
- · 12,650,000 Class A shares at ~$10.48 redemption value (2025) vs $10.05 (2024).
14-05-2026
This DEFM14A proxy statement for Mountain Lake Acquisition Corp. (MLAC) outlines risks associated with the proposed Business Combination with Pubco, including its status as an emerging growth company under the JOBS Act, reliance on disclosure exemptions, potential internal control weaknesses, litigation exposure, advisory board conflicts, post-merger stock volatility, and conditions to closing such as shareholder approval and Nasdaq listing that may not be satisfied. No positive operational metrics are provided, emphasizing uncertainties like material adverse effects or failure to meet analyst expectations. The filing highlights potential declines in Pubco Class A Stock price due to market factors unrelated to performance.
- · Business Combination conditions include MLAC shareholder approval, no prohibiting laws/orders, effectiveness of proxy statement/prospectus, Nasdaq listing approval, accuracy of representations/warranties, covenant performance, no material adverse effect on MLAC/Pubco/Company, and completion of Contribution.
- · Pubco expected to remain emerging growth company until earliest of fifth anniversary post-Business Combination, $1.235B revenue, $700M non-affiliate market value, or $1B debt issuance.
- · Advisory Board members have affiliations that may lead to conflicts, such as resource allocation or partnership decisions diverging from Pubco interests.
14-05-2026
NEC Corporation, through its wholly owned subsidiary Netcracker Technology, announced the completion of its acquisition of CSG Systems International, Inc. on May 14, 2026. Netcracker will lead the combined operations with Andrew Feinberg appointed as Chairman and Chief Executive Officer, enhancing capabilities in customer engagement, monetization, AI-driven automation, and cloud-native platforms. The merger aims to deliver integrated solutions for telecom, broadband, and digital service providers, with no reported disruptions to customer services.
- · NEC Group was established in 1899.
- · Netcracker Technology has over three decades of experience in digital platforms.
14-05-2026
Off The Hook YS Inc. (NYSE American: OTH) completed the acquisition of Apex Marine Companies (APEX) on May 14, 2026, gaining South Florida facilities with haul-out capacity up to 150 metric tons and support for vessels up to 130 feet, enhancing operational efficiency, refurbishment capacity, and global sales reach. The integration is generating millions of dollars in annual cost savings through reduced third-party dependencies, lower transportation costs, and faster turnaround times. This creates a centralized hub for tens of millions of dollars in inventory near Fort Lauderdale and Miami within the $57 billion U.S. marine industry.
- · APEX facilities support haul-out up to 150 metric tons and vessels up to 130 feet
- · Company founded in 2012 and headquartered in Wilmington, North Carolina
14-05-2026
Biogen Inc. completed its acquisition of Apellis Pharmaceuticals, Inc. on May 14, 2026, making Apellis a wholly owned subsidiary and adding EMPAVELI® and SYFOVRE® products, which generated $689 million in net product revenue in 2025. The deal is expected to be accretive to Biogen’s Non-GAAP diluted EPS in 2027 and boost EPS CAGR through the decade, while enhancing launch readiness for felzartamab with Phase 3 data anticipated in H1 2027. Approximately 82.4% of Apellis shares (105,687,831 shares) were tendered at $41 per share in cash plus a contingent value right (CVR) up to $4 per share.
- · Tender offer expired one minute after 11:59 p.m. ET on May 13, 2026; all conditions satisfied or waived on May 14, 2026.
- · Apellis shares ceased trading on Nasdaq following the merger.
- · Updated financial guidance to be provided with Q2 earnings report in July 2026.
- · Phase 3 readout for felzartamab in antibody-mediated rejection in kidney transplant patients expected in first half of 2027.
14-05-2026
Sumitomo Forestry Co., Ltd. completed its acquisition of Tri Pointe Homes, Inc. for $47.00 per share on May 14, 2026, making Tri Pointe a wholly owned subsidiary of Sumitomo Forestry America, Inc. and causing it to cease trading on the NYSE. The deal integrates Tri Pointe's premium lifestyle brand, over 160 active communities across 13 states, positioning the combined entity as the 5th largest U.S. homebuilder delivering approximately 15,000 units annually across 18 states. Leadership from both companies expressed enthusiasm for accelerated growth toward the Mission TREEING 2030 goal of 23,000 U.S. homes annually by 2030.
- · Tri Pointe Homes recognized as one of the 2026 Fortune World’s Most Admired Companies, 2026 Fortune 100 Best Companies to Work For, PEOPLE Companies That Care (2023-2025), Great Place To Work-Certified for five years.
- · Advisors: Mitsubishi UFJ Morgan Stanley and Morrison & Foerster LLP for Sumitomo Forestry; Moelis & Company LLC and Paul Hastings LLP for Tri Pointe Homes; Collected Strategies for communications.
Get daily alerts with 12 investment signals, 10 risk alerts, 10 opportunities and full AI analysis of all 16 filings
More from: US Merger & Acquisition SEC Filings
🇺🇸 More from United States
View all →May 06, 2026
US Pre-Market SEC Filings Roundup — May 06, 2026
US Pre-Market SEC Filings Roundup
May 06, 2026
New Drug Approvals (Original) — May 06, 2026
New Drug Approvals (Original)
May 06, 2026
Orphan Drug Approvals — May 06, 2026
Orphan Drug Approvals
May 06, 2026
Biotech Small-Cap Approvals — May 06, 2026
Biotech Small-Cap Approvals